With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

With its FDA pitch on the Alzheimer’s drug ad­u­canum­ab hang­ing per­ilous­ly close to dis­as­ter, Bio­gen is rolling the dice on a $3.1 bil­lion deal that brings in com­mer­cial rights to one of the oth­er spot­light neu­ro drugs in late-stage de­vel­op­ment — af­ter it al­ready failed its first Phase III.

The big biotech has turned to Sage Ther­a­peu­tics for its lat­est deal, close to a year af­ter the crush­ing fail­ure of Sage-217, now dubbed zu­ra­nolone, in the MOUN­TAIN study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER